148 related articles for article (PubMed ID: 34866347)
1. Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: A 3-year follow-up.
Furusawa A; Wakiguchi H; Okazaki F; Korenaga Y; Azuma Y; Yasudo H; Hasegawa S
Int J Rheum Dis; 2022 Jan; 25(1):95-96. PubMed ID: 34866347
[No Abstract] [Full Text] [Related]
2. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
Vanthuyne M; Blockmans D; Westhovens R; Roufosse F; Cogan E; Coche E; Nzeusseu Toukap A; Depresseux G; Houssiau FA
Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
[TBL] [Abstract][Full Text] [Related]
3. New developments in juvenile systemic and localized scleroderma.
Foeldvari I
Rheum Dis Clin North Am; 2013 Nov; 39(4):905-20. PubMed ID: 24182860
[TBL] [Abstract][Full Text] [Related]
4. Scleroderma in children.
Zulian F
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):576-595. PubMed ID: 29773274
[TBL] [Abstract][Full Text] [Related]
5. Treatment in Juvenile Scleroderma.
Zulian F; Tirelli F
Curr Rheumatol Rep; 2020 Jun; 22(8):45. PubMed ID: 32591919
[TBL] [Abstract][Full Text] [Related]
6. Case of juvenile localized scleroderma with joint sclerosis and Sjögren's syndrome in a child with precocious puberty.
Kim HS; Choi YJ; Park YM; Kim HO; Lee JY
J Dermatol; 2011 Oct; 38(10):1024-7. PubMed ID: 21658114
[No Abstract] [Full Text] [Related]
7. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
Nevskaya T; Baron M; Pope JE;
Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
[TBL] [Abstract][Full Text] [Related]
8. [Systemic sclerosis (scleroderma) without scleroderma].
Nadashkevych ON
Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
[TBL] [Abstract][Full Text] [Related]
9. Presentations and treatment of childhood scleroderma: localized scleroderma, eosinophilic fasciitis, systemic sclerosis, and graft-versus-host disease.
Hedrich CM; Fiebig B; Hahn G; Suttorp M; Gahr M
Clin Pediatr (Phila); 2011 Jul; 50(7):604-14. PubMed ID: 21525084
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
Soh HJ; Samuel C; Heaton V; Renton WD; Cox A; Munro J
Rheumatol Int; 2019 May; 39(5):933-941. PubMed ID: 30838436
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
[TBL] [Abstract][Full Text] [Related]
13. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.
Hinchcliff M; Huang CC; Wood TA; Matthew Mahoney J; Martyanov V; Bhattacharyya S; Tamaki Z; Lee J; Carns M; Podlusky S; Sirajuddin A; Shah SJ; Chang RW; Lafyatis R; Varga J; Whitfield ML
J Invest Dermatol; 2013 Aug; 133(8):1979-89. PubMed ID: 23677167
[TBL] [Abstract][Full Text] [Related]
14. Scleroderma in children: an update.
Zulian F; Cuffaro G; Sperotto F
Curr Opin Rheumatol; 2013 Sep; 25(5):643-50. PubMed ID: 23912318
[TBL] [Abstract][Full Text] [Related]
15. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma.
Li SC; Torok KS; Ishaq SS; Buckley M; Edelheit B; Ede KC; Liu C; Rabinovich CE
Rheumatology (Oxford); 2021 Aug; 60(8):3817-3825. PubMed ID: 33369667
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of scleroderma.
Adnan ZA
Acta Med Indones; 2008 Apr; 40(2):109-12. PubMed ID: 18560030
[TBL] [Abstract][Full Text] [Related]
18. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.
Martini G; Saggioro L; Culpo R; Vittadello F; Meneghel A; Zulian F
Rheumatology (Oxford); 2021 Mar; 60(3):1387-1391. PubMed ID: 32978631
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials for the treatment of systemic sclerosis/scleroderma.
Varga J; Ponor I
Curr Rheumatol Rep; 1999 Oct; 1(1):13-4. PubMed ID: 11123008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
